<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        5-5173-19
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        PREXET 500 mg Pow for Concentrate for Sol for Inf
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PEMETREXED
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for concentrate for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        2883.5
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Gensenta &#x130;la&#xE7; Sanayi ve Ticaret A.&#x15E;" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Gensenta İlaç Sanayi ve Ticaret A.Ş
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            GENSENTA İLAÇ SANAYI VE TICARET A.Ş
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01BA04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>PREXET is a white to light yellow or yellow-green coloured lyophilized powder. The solution prepared by dissolving in 0.9% sodium chloride solution is clear colorless-yellow or yellow- green colored. PREXET is a powder for concentrate for solution for infusion in a vial. Each pack of PREXET consists of one vial.</p><p>&nbsp;</p><p>20 ml of sodium chloride (0.9 %) solution for injection is added to 50 ml vial to obtain a solution containing 25 mg pemetrexed per ml. Further dilution by a healthcare provider may be required prior to administration when necessary. Following preparation of solution it is administered into vein slowly.</p><p>&nbsp;</p><p>PREXET is a medicine used in the treatment of cancer.</p><p>&nbsp;</p><p>PREXET is used in combination with cisplatin, another anti-cancer medicine, as treatment for malignant pleural mesothelioma, a form of cancer that affects the lining of the lung, to patients who have not received prior chemotherapy.</p><p>PREXET is also given in combination with cisplatin for the initial treatment of patients with advanced stage of lung cancer who have not received prior chemotherapy.</p><p>&nbsp;</p><p>PREXET can be prescribed to you if you have lung cancer at an advanced stage if your disease has responded to treatment or it remains largely unchanged after initial chemotherapy.</p><p>&nbsp;</p><p>PREXET is also a treatment for patients with advanced stage of lung cancer whose disease has progressed after other initial chemotherapy has been used.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a. Do not USE PREXET;</strong></p><p>If,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You are hypersensitive (allergic) to pemetrexed or to any of the other ingredients of PREXET.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You are breast-feeding, breast-feeding should be discontinued during treatment with PREXET.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;You have recently received or are about to receive a vaccine against yellow fever.</p><p><strong>&nbsp;</strong></p><p><strong>b. Take SPECIAL </strong><strong>CARE </strong><strong>with PREXET:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; If you currently have or have previously had problems with your kidneys, talk to your doctor or hospital pharmacist as you may not be able to receive PREXET. Before each infusion you will have samples of your blood taken to evaluate if you have sufficient kidney and liver function and to check that you have enough blood cells to receive PREXET. Your doctor may decide to change the dose or delay treating you depending on your general condition and if your blood cell counts are too low.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; If you are also receiving cisplatin, your doctor will make sure that you are properly hydrated and receive appropriate treatment before and after receiving cisplatin to prevent vomiting.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; If you have had or are going to have radiation therapy, please tell your doctor, as there may be an early or late radiation reaction with PREXET.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; If you have been &nbsp;recently vaccinated, please tell your doctor, as this can possibly cause bad effects with PREXET.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; If you have an accumulation of fluid around your lungs, your doctor may decide to remove the fluid before giving you PREXET.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; If male patients would like to father a child during the treatment or in the 6 months following receipt of treatment, they should seek advice from a doctor or pharmacist. Owing to the possibility of pemetrexed treatment causing irreversible infertility, male patients are advised to seek counseling on sperm storage before starting treatment.</p><p>&nbsp;</p><p>If these warnings are valid for you, even for a period of time in the past, please consult your doctor.</p><p><strong>&nbsp;</strong></p><p><strong>c. Using other medicines:</strong><em> </em></p><p>Please tell your doctor if you are taking any medicine for pain or inflammation (swelling), including medicines known as &ldquo;non-steroidal anti-inflammatory drugs&rdquo; (NSAIDs) (such as ibuprofen) and medicines purchased without a doctor&rsquo;s prescription (such as aspirin). There are many sorts of NSAIDs with different durations of activity. Based on the planned date of administration of PREXET and/or on the status of your kidney function, your doctor needs to advise you on which medicines you can take and when you can take them. If you are unsure, ask your doctor or pharmacist if any of your medicines are NSAIDs.</p><p><em>&nbsp;</em></p><p><em>Please inform your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained with or without prescription.</em></p><p><strong>&nbsp;</strong></p><p><strong>d. Using PREXET with food and drink</strong></p><p>There is no interaction with food and drink in term of method of administration.</p><p>&nbsp;</p><p><strong>e. Pregnancy &amp; Breastfeeding</strong></p><p><strong>P</strong><strong>r</strong><strong>e</strong><strong>gnancy</strong></p><p><em>Consult your doctor or pharmacist before using this medicine.</em></p><p>&nbsp;</p><p>If you are pregnant, or thinking about becoming pregnant, <strong>tell your doctor</strong>. The use of PREXET should be avoided during pregnancy. Your doctor will discuss with you the potential risk of taking PREXET during pregnancy. Women must use effective contraception during treatment with PREXET.</p><p><em>&nbsp;</em></p><p><em>During your treatment, if you realize that you are pregnant, consult to your doctor or pharmacist immediately.</em></p><p><em>&nbsp;</em></p><p><strong>Breast-feeding </strong></p><p><em>Consult your doctor or pharmacist before using this medicine.</em></p><p>&nbsp;</p><p>It is not known whether PREXET passes to breast milk. Therefore, breast-feeding should be discontinued during PREXET treatment.</p><p>&nbsp;</p><p><strong>Fertility</strong></p><p>Men are advised not to father a child during and up to 6 months following treatment with PREXET and should therefore use effective contraception during treatment with PREXET and for up to 6 months afterwards. If you would like to father a child during the treatment or in the 6 months following receipt of treatment, seek advice from your doctor or pharmacist. You may want to seek counselling on spermstorage before starting your therapy.</p><p>&nbsp;</p><p><strong>f. Driving and using machines </strong></p><p>PREXET may cause fatigue. If you feel fatigue avoid driving a car or using machines that require attention.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>g. Important information about some of the ingredients of PREXET</strong></p><p>This medicinal product contains approximately 54 mg of sodium per vial. To be taken into consideration by patients on a controlled sodium diet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><em>Always use PREXET exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.</em></p><p>&nbsp;</p><p><strong>Instructions for proper use and dosage/frequency of administration:</strong><strong> </strong></p><p>The dose of PREXET is 500 mg for every square meter of your body&rsquo;s surface area. Your height and weight are measured to work out the surface area of your body. Your doctor will use this body surface area to decide the right dose for you. This dose may be adjusted, or treatment may be delayed depending on your blood cell counts and on your general condition. A hospital pharmacist, nurse or doctor will have mixed the PREXET powder with (0.9 %) sodium chloride solution for injection before it is given to you.</p><p><strong>&nbsp;</strong></p><p><strong>Method and route of administration:</strong></p><p>PREXET will always be administrated by infusion into one of the veins (intravenous). The infusion will last approximately 10 minutes.</p><p>&nbsp;</p><p><em>When using PREXET in combination with cisplatin: </em></p><p>The doctor or hospital pharmacist will work out the dose you need based on your height and weight. Cisplatin is also given by infusion into one of your veins for 2 hours, and is given approximately 30 minutes after the infusion of PREXET has finished.</p><p>You should usually receive your infusion once every 3 weeks.</p><p>&nbsp;</p><p><em>Additional medicines: </em></p><p>Corticosteroids: Your doctor will prescribe you steroid tablets (equivalent to 4 milligram of dexamethasone twice a day) that you will need to take on the day before, on the day of, and the day after PREXET treatment. This medicine is given to you to reduce the frequency and severity of skin reactions that you may experience during your anticancer treatment.</p><p><strong>&nbsp;</strong></p><p>Consult your doctor about supportive vitamins.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p><p><strong>&nbsp;</strong></p><p><strong>Different age groups:</strong></p><p><strong>&nbsp;</strong></p><p><strong>Use in children: </strong></p><p>Since the safety and efficacy in this patient group has not been investigated, PREXET is not recommended using in patients under 18 years old.</p><p>&nbsp;</p><p><strong>Use in elderly: </strong></p><p>No dose reduction is necessary other than the recommended dose in patients 65 years old or older.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Special conditions for use:</strong></p><p><strong>&nbsp;</strong></p><p><strong>Kidney/ Liver insufficiency:</strong></p><p>In clinical studies patients with mild kidney function disorder have not required any dose adjustment other than the recommended for all patients. There are insufficient data available on renal patients, therefore usage of PREXET is not recommended in these patients.</p><p>&nbsp;</p><p>Before each dose blood cells count, blood tests to evaluate kidney and liver function will be performed. Your doctor may decide to change the dose or delay treating you according to your test results.</p><p>&nbsp;</p><p>Follow these instructions unless advised otherwise by your doctor.</p><p>Do not forget take your medicine on time.</p><p>&nbsp;</p><p>You doctor will inform you how long will your treatment will continue with PREXET. Do not stop your treatment early, thus the desired result cannot be achieved.</p><p>&nbsp;</p><p><em>If you have an impression that </em><em>the effect of </em><em>PREXET is too strong or weak, please contact to your doctor or pharmacist.</em></p><p>&nbsp;</p><p><strong>a. If you use more PREXET than you should</strong></p><p>It is very unlikely that you will receive an overdose, as this medicine will be administered by a doctor or nurse. But if you think that you have more medicine than you should receive, please tell immediately to your doctor or nurse.</p><p><strong>&nbsp;</strong></p><p><strong>b. If you forget to use PREXET</strong></p><p>Your doctor will decide when the missing dose will be administered. It is important to follow your doctor instructions for the new administration time for the following dose.</p><p><strong>&nbsp;</strong></p><p><em>Do not take a double dose to make up for a forgotten dose.</em></p><p><strong>&nbsp;</strong></p><p><strong>c. If you stop using PREXET </strong></p><p>No data available.</p><p>&nbsp;</p><p><em>If you have any further questions on the use of this product, ask your doctor or pharmacist.</em></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Serious side effects</strong></p><p><strong>&nbsp;</strong></p><p><strong>If you notice any of the following, </strong><strong>contact your doctor immediately</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever or infection (common): if you have a temperature of 38&ordm;C or greater, sweating or other&nbsp; signs of infection (since you might have less white blood cells than normal which is very common).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you start feeling chest pain (common) or change in heart rate (fast or irregular) (uncommon),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have pain, redness, swelling or sores in your mouth (very common),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic reaction: if you develop swelling of the hands, feet, wrist, face, lips or swelling of mouth and throat causing difficulty in swallowing or breathing and skin rash (very common) or fever (common), burning or prickling sensation (common)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you experience tiredness, feeling faint, becoming easily breathless or if you look pale (since you might have less hemoglobin than normal which is very common),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you experience bleeding (from the gums, nose or mouth or any bleeding) that would not stop, reddish or pinkish urine, unexpected bruising (since you might have less platelets than normal which is very common).</p><p><strong>Possible side effects:</strong></p><p>&nbsp;</p><p>Like all medicines, PREXET can cause side effects although not everybody gets them.</p><p>&nbsp;</p><p>Side effects with PREXET may include:</p><p>&nbsp;</p><p>Very common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low white blood cells, low hemoglobin level (anaemia), low platelet count, diarrhoea, vomiting, pain, redness, swelling or sores in your mouth, nausea, loss of appetite, fatigue, skin rash, hair loss, constipation, loss of sensation, kidney abnormal blood tests.</p><p>&nbsp;</p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic reactions (skin rash / burning or prickling sensation), infection, fever, dehydration, kidney failure (the condition where increased blood urea level and kidneys are no longer working sufficiently with symptoms of excessive consumption of water, frequent urinating), irritation of the skin and itching, chest pain, muscle weakness, inflamed eye (conjunctivitis), upset stomach, pain in the abdomen, taste change, liver abnormal blood tests, watery eyes.</p><p>&nbsp;</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fast heart rate, inflammation of the lining of the esophagus with PREXET/ radiation therapy (inflammatory condition in the esophagus with a burning sensation), inflammation of the lining of the large bowel, which may be accompanied by intestinal or rectal bleeding (colitis), scarring of the air sacs of the lung (interstitial pneumonitis), excess fluid in body tissue, causing swelling (oedema). Some patients have experienced stroke while receiving PREXET usually in combination with another anticancer therapy.</p><p>&nbsp;</p><p>Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Radiation recall reaction, a skin rash like severe sunburn which can occur on skin that has previously been exposed to radiotherapy, from days to years after the radiation.</p><p>&nbsp;</p><p>You might have any of these symptoms and/or conditions. You must tell your doctor as soon as possible when you start experiencing any of these side effects.</p><p>&nbsp;</p><p>Unknown:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Scarring of the air sacs of the lung associated with radiation therapy (radiation pneumonitis) may occur in patients who are also treated with radiation before, or during their PREXET therapy, pain in arms and legs, low temperature and discoloration.</p><p>&nbsp;</p><p>If you are concerned about any side effects, talk to your doctor.</p><p>&nbsp;</p><p><em>If any of the side effects gets serious, or if you notice any side effect not listed in this leaflet, please tell your doctor or pharmacist.</em></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><em>Keep PREXET out of the reach and sight of children and store it in its package. </em></p><p><em>&nbsp;</em></p><p>Do not store unopened vials above 30&ordm;C.</p><p>&nbsp;</p><p>Diluted infusion solutions should be used immediately. When prepared as directed, infusion solutions of reconstituted and diluted pemetrexed should be kept at between 2&deg;C to 8&deg;C in 24 hours.</p><p>&nbsp;</p><p>For single use only. Any unused medicinal product or waste material must be disposed of in accordance with local requirements.</p><p>&nbsp;</p><p><strong>Use in accordance with the expiry date.</strong></p><p><em>&nbsp;</em></p><p><em>Do not use PREXET after the expiry date which is stated on the package.</em> <em>The expiry date refers to the last day of that month.</em></p><p><em>&nbsp;</em></p><p><em>Do not use PREXET if you notice any defect in the product and/or on its packaging. </em></p><p><em>&nbsp;</em></p><p><em>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</em></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong><em>Active Substance:</em></strong> Each vial contains&nbsp; 604.13 mg pemetrexed disodium hemipentahydrate as powder equivalent to 500 mg pemetrexed. Following reconstitution with 20 ml (0.9%) sodium chloride solution each ml of the obtained solution contains 25 mg pemetrexed.</p><p><strong><em>&nbsp;</em></strong></p><p><strong><em>Excipient(s):</em></strong> Mannitol, sodium hydroxide solution and hydrochloric acid solution for pH adjustment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                PREXET is lyophilized powder in colorless 50 ml Type I glass vial with rubber stopper and flip-off aluminum cap, in protective blister separator, containing 500 mg pemetrexed. 
Available in packs of 1 vial accompanied by patient information leaflet.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>MN Pharmaceuticals</p><p>Pak İş Merkezi, Prof. Dr. B&uuml;lent Tarcan Sok.,</p><p>No: 5/1, 34349 Gayrettepe/Istanbul</p><p>TURKEY</p><p>Tel: 0212 337 38 00</p><p>Fax: +90.212.337 38 01</p><p>e-mail: info@mn.com.tr</p><p><strong>&nbsp;</strong></p><p><strong>Manufacturer:<em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></strong></p><p>MN Pharmaceuticals</p><p>Sanayi Cad. No: 66</p><p>Yenibosna &ndash; Bah&ccedil;elievler - Istanbul</p><p>TURKEY</p><p><em>&nbsp;</em></p><p><em>For any information about this medicinal product, please contact the local representative of the Marketing Authorization Holder:</em></p><p>Kingdom of Saudi Arabia</p><p>Salehiya Trading Est.</p><p>P.O. Box: 991 Riyadh: 11421</p><p>Tel. No.: +966 11 464 6955</p><p>Fax No.: +966 11 463 4362</p><p>Website: www.salehiya.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved in 12/2018; version number 03
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">بريكسيت هو مسحوق مجفف بالتجميد بلون أبيض إلى أصفر فاتح أو أخضر مصفر. لون المحلول المحضر عن طريق تذويبه في 0.9٪ محلول كلوريد الصوديوم هو صافي عديم اللون إلى مصفر أو أخضر مصفر. بريكسيت هو مسحوق مركز لمحلول التشريب الوريدي في قارورة. كل عبوة من بريكسيت تتكون من قارورة واحدة.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">يتم إضافة 20 مل من محلول كلوريد الصوديوم (0.9٪) للحقن إلى قارورة 50 مل للحصول على محلول يحتوي على 25 ملغم بيميتريكسد لكل مل. قد يكون من الضروري التخفيف الاضافي من قبل مقدم الرعاية الصحية قبل الاستخدام عند الحاجة. بعد إعداد المحلول يتم إعطاؤه في الوريد ببطء.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">بريكسيت هو دواء يستخدم في علاج السرطان.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">يستخدم بريكسيت بالتزامن مع سيسبلاتين (دواء آخر مضاد للسرطان) كعلاج لورم الظهارة المتوسطة الجنبي الخبيث، وهو شكل من أشكال السرطان الذي يؤثر على بطانة الرئة وذلك للمرضى الذين لم يتلقوا العلاج الكيميائي من قبل<strong>.</strong></p><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">يعطى بريكسيت أيضا بالتزامن مع سيسبلاتين للعلاج الأولي للمرضى الذين يعانون من مرحلة متقدمة من سرطان الرئة الذين لم يتلقوا العلاج الكيميائي من قبل.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">من الممكن وصف بريكسيت لك إذا كان لديك سرطان الرئة في مرحلة متقدمة في حال كان مرضك استجاب للعلاج أو ما زال بشكل كبير دون تغيير بعد العلاج الكيميائي الأولي.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">بريكسيت هو أيضا علاج للمرضى الذين يعانون من مرحلة متقدمة من سرطان الرئة حيث تقدم مرضهم بعد استخدام العلاج الكيميائي الأولي الآخر.</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>&zwnj;أ.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>لا تستخدم بريكسيت؛</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">إذا،&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp; كنت تعاني من حساسية مفرطة (تحسس) لبيميتريكسد أو إلى أي من المكونات الأخرى من بريكسيت.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp; كنت مرضعة، يجب وقف الرضاعة الطبيعية أثناء العلاج باستخدام بريكسيت.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp; تلقيت مؤخرا أو على وشك تلقي لقاح ضد الحمى الصفراء.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>&zwnj;ب.&nbsp;&nbsp;&nbsp; </strong><strong>تعامل مع بريكسيت بعناية خاصة:</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp; إذا كنت تعاني حاليا أو سابقا من مشاكل في الكلى، تحدث مع طبيبك أو الصيدلي في المستشفى حيث أنه قد لا تتمكن من استخدام بريكسيت. قبل كل تشريب سيتم أخذ عينات من دمك لتقييم ما إذا كانت وظائف الكلى والكبد فعالة والتحقق من أن لديك ما يكفي من خلايا الدم لتلقي بريكسيت. قد يقرر طبيبك تغيير الجرعة أو تأخير علاجك اعتمادا على حالتك العامة وإذا كان تعداد خلايا الدم منخفض جدا.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp; إذا كنت تتلقى سيسبلاتين أيضا، سوف يتأكد طبيبك من أنك تحصل على الماء بشكل صحيح وتحصل على العلاج المناسب قبل وبعد تلقي سيسبلاتين لمنع القيء.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp; إذا كنت تلقيت أو ستتلقى علاج بالاشعة، فيرجى إخبار طبيبك بذلك، حيث قد يكون هنالك تفاعل إشعاعي مبكر أو مؤجل مع بريكسيت.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp; إذا كنت قد تلقيت تطعيما مؤخرا، فيرجى إخبار طبيبك، لأن هذا قد يسبب اعراض سيئة مع بريكسيت.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp; إذا كان لديك تراكم في السوائل حول الرئتين، فقد يقرر الطبيب إزالة السوائل قبل إعطائك بريكسيت.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp; إذا كان المرضى الذكور يرغبون في أبوّة طفل خلال فترة العلاج أو خلال 6 أشهر التالية لتلقي العلاج، يجب عليهم طلب المشورة من طبيب أو صيدلي. نظرا لإمكانية تسبب علاج البيميتريكسد بالعقم الغير قابل للعكس لهذا ينصح المرضى الذكور بالحصول على المشورة بشأن تخزين الحيوانات المنوية قبل بدء العلاج.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">إذا كانت هذه التحذيرات تنطبق عليك حتى لو لفترة سابقة من الزمن فيرجى استشارة طبيبك.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>&zwnj;ج.&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>استخدام أدوية أخرى:</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">یرجی إخبار طبیبك إذا کنت تتناول أي أدوية للألم أو الالتھاب (تورم)، بما في ذلك الأدویة المعروفة باسم &quot;الأدوية المضادة للالتھاب غیر الستيروئیدیة &quot; (مثل أيبوبروفین) والأدویة المباعة دون وصفة طبیة (مثل الأسبیرین). هناك العديد من أنواع مضادات الالتهاب غير الستيروئيدية مع فترات مختلفة من الفعالية. استنادا إلى الموعد المقرر لإعطاء بريكسيت و / أو على حالة وظيفة الكلى لديك، يجب على الطبيب أن يقدم لك المشورة بشأن الأدوية التي يمكنك أخذها ومتى يمكنك أخذها. إذا كنت غير متأكد، اسأل طبيبك أو الصيدلي إذا كان أي من أدويتك هي من مضادات الالتهاب غير الستيروئيدية.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><em>يرجى اعلام طبيبك أو الصيدلي في حال كنت تأخذ أو أخذت مؤخراً أية أدوية أخرى، بما في ذلك الأدوية التي تم الحصول عليها بدون وصفة طبية.</em></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>&zwnj;د.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>استخدام بريكسيت مع الطعام و الشراب</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">لا يوجد تفاعل مع الطعام أو الشراب نظرا لطريقة استخدامه.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>&zwnj;ه.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>الحمل والرضاعة</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>الحمل</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><em>استشر طبيبك أو الصيدلي قبل استخدام هذا الدواء.</em></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">إذا كنت حاملا، أو تفكرين في الحمل، <strong>أخبري طبيبك</strong>. ينبغي تجنب استخدام بريكسيت خلال فترة الحمل. سوف يناقش طبيبك معك المخاطر المحتملة لأخذ بريكسيت أثناء الحمل. يجب على النساء استخدام وسائل منع الحمل الفعالة أثناء العلاج باستخدام بريكسيت.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><em>خلال فترة العلاج، اذا علمت أنك حامل، استشيري طبيبك او الصيدلي فوراً.</em></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>الرضاعة </strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><em>استشر طبيبك أو الصيدلي قبل تناول هذا الدواء.</em></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">من غير المعروف ما إذا كان بريكسيت ينتقل إلى حليب الثدي. لذلك، ينبغي وقف الرضاعة الطبيعية أثناء العلاج باستخدام بريكسيت.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>الخصوبة</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">ينصح الرجال بعدم التوالد خلال العلاج و لفترة تصل إلى 6 أشهر بعد العلاج ببريكسيت، وبالتالي يجب استخدام وسائل منع حمل فعالة خلال فترة العلاج ببريكسيت و لمدة تصل إلى 6 أشهر بعد ذلك. إذا كنت ترغب في التوالد أثناء فترة العلاج أو لفترة 6 أشهر بعد تلقي العلاج، فاستشر طبيبك أو الصيدلي. قد ترغب في الحصول على استشارة بشأن تخزين الحيوانات المنوية قبل بدء العلاج.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>&zwnj;و.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>القيادة واستخدام الآلات</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">قد يسبب بريكسيت الارهاق. إذا كنت تشعر بالارهاق تجنب قيادة السيارة أو استخدام الآلات التي تتطلب التركيز.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>&zwnj;ز.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>معلومات مهمة حول بعض مكونات بريكسيت</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">للأخذ بعين الاعتبار من قبل المرضى الذين يتبعون نظام غذائي محدد الصوديوم حيث يحتوي هذا المنتج الطبي على ما يقارب 54 ملغم من الصوديوم لكل قارورة.</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><em>يجب استخادم بريكسيت دائماً كما اخبرك طبيبك تماما. يجب مراجعة طبيبك أو الصيدلي إن كنت غير متأكد.</em></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>تعليمات الاستخدام الصحيح والجرعة / تكرار الاستخدام:</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">الجرعة من بريكسيت هي 500 ملغم لكل متر مربع من مساحة سطح جسمك. يتم قياس طولك ووزنك لحساب مساحة سطح جسمك. سيستخدم طبيبك مساحة سطح الجسم المحسوبة لتحديد الجرعة المناسبة لك. قد يتم تعديل هذه الجرعة، أو قد يتم تأخير العلاج اعتمادا على تعداد خلايا الدم وعلى حالتك العامة. سوف يخلط الصيدلي أو الممرضة أو الطبيب في المستشفى مسحوق بريكسيت مع (0.9٪) محلول كلوريد الصوديوم للحقن قبل إعطائه لك.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>طريق الاستخدام و طريقته:</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">سيتم إعطاء بريكسيت دائما عن طريق التشريب في واحد من الأوردة (عن طريق الوريد). وسيستمر التشريب لمدة 10 دقائق تقريبا.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><em>عند استخدام بريكسيت بالتزامن مع سيسبلاتين:</em></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">سيقوم الطبيب أو الصيدلي في المستشفى بحساب الجرعة التي تحتاج إليها بناء على طولك والوزن. يتم إعطاء سيسبلاتين أيضا عن طريق التشريب في واحد من الأوردة لمدة&nbsp; ساعتين، ويعطى بعد 30 دقيقة تقريبا من الانتهاء من التشريب ببريكسيت<strong>.</strong></p><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">ستتلقى التشريب عادة مرة واحدة كل 3 أسابيع.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><em>أدوية إضافية:</em></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">الكورتيكوستيرويدات: سيقوم الطبيب بوصف أقراص الستيرويد لك (ما يعادل 4 مليغرام من ديكساميثازون مرتين في اليوم) والتي يجب عليك أخذها في اليوم السابق، وفي نفس اليوم، وبعد يوم من العلاج ببريكسيت. يتم إعطاؤك هذا الدواء للحد من تكرر وشدة ردود فعل الجلد التي قد تواجهها أثناء علاجك ضد السرطان.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">استشر طبيبك حول الفيتامينات الداعمة.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء، اسأل طبيبك أو الصيدلي.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>الفئات العمرية المختلفة:</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>الاستخدام في الاطفال:</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">بما أنه لم يتم التحقيق بالسلامة والفعالية في هذه المجموعة من المرضى، فلا ينصح باستخدام بريكسيت في المرضى الذين تقل أعمارهم عن 18 سنة.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>الاستخدام في كبار السن:</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">لا ضرورة لخفض الجرعة عن الموصى به في المرضى الذين تتراوح أعمارهم بين 65 سنة أو أكثر.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>شروط خاصة للاستخدام:</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>قصور الكلى / الكبد:</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">في الدراسات السريرية، المرضى الذين يعانون من اضطراب خفيف في وظائف الكلى لم يتطلب أي تعديل للجرعة الموصى بها لجميع المرضى. لا تتوفر بيانات كافية عن مرضى الكلى، لذلك لا ينصح باستخدام بريكسيت لهؤلاء المرضى.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">قبل كل جرعة سيتم تعداد خلايا الدم ، وسيتم إجراء فحوصات الدم لتقييم وظائف الكلى والكبد. قد يقرر طبيبك تغيير الجرعة أو تأخير علاجك وفقا لنتائج فحوصاتك.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">اتبع هذه التعليمات ما لم ينصحك طبيبك خلاف ذلك.</p><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">لا تنسى تناول الدواء في الوقت المحدد.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">سيقوم طبيبك بإبلاغك كم من الوقت سيستمر علاجك باستخدام بريكسيت. لا توقف العلاج قبل موعده المحدد، إذ أنه لا يمكن تحقيق النتيجة المرجوة.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><em>إذا كان لديك الانطباع ان تأثير </em><em>بريكسيت</em><em> قوي جداً أو ضعيف جداً، يرجى الاتصال بطبيبك او الصيدلي.</em></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>&zwnj;أ.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>إذا استخدمت بريكسيت أكثر من اللازم</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">من المستبعد جدا أن تأخذ جرعة زائدة، لأن هذا الدواء سوف يتم إعطاؤه من قبل طبيب أو ممرضة. ولكن إذا كنت تعتقد أنك أخذت دواء أكثر من اللازم أخذه، من فضلك أخبر طبيبك أو الممرضة فوراً.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>&zwnj;ب.&nbsp;&nbsp;&nbsp; </strong><strong>إذا نسيت أن تستخدم بريكسيت</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">سوف يقرر طبيبك متى يجب أخذ الجرعة التي فاتتك. من المهم أن تتبع أوامر طبيبك عن وقت الاستخدام الجديد للجرعة التالية.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><em>لا تأخذ جرعة مضاعفة لتعويض الجرعة التي نسيتها.</em></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>&zwnj;ج.&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>إذا توقفت عن استخدام بريكسيت</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">لا تتوفر أي معلومات.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><em>إذا كان لديك أي أسئلة أخرى حول استخدام هذا المنتج، اسأل طبيبك أو الصيدلي.</em></p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>أعراض جانبية خطيرة:</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>إذا لاحظت أي مما یلي، اتصل بطبیبك فورا</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى أو عدوى (شائع): إذا بلغت درجة حرارتك 38 &deg;م أو أكثر، تعرق أو أي علامات أخرى للالتهاب (حيث قد يكون لديك عدد خلايا الدم البيضاء أقل من المعتاد وهو أمر شائع جدا).</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا بدأت تشعر بألم في الصدر (شائع) أو تغير في معدل ضربات القلب (سريع أو غير منتظم)&nbsp; (غير شائع)</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>إذا كان لديك ألم ، احمرار، انتفاخ أو قروح في فمك (شائع جدا) ،</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رد فعل تحسسي: إذا اصبح لديك انتفاخ في اليدين، القدمين، المعصم، الوجه، الشفتين أو انتفاخ في الفم والحلق مما يسبب صعوبة في البلع أو التنفس، الطفح الجلدي (شائع جدا) أو الحمى (شائع) ، أو الشعور بالحرق أو الوخز (شائع)</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا شعرت بالتعب، الشعور بالإغماء، أو أن تصبح منقطع النفس بسهولة أو إذا كنت تبدو شاحباً (حيث قد يكون لديك هيموجلوبين أقل من المعتاد وهو أمر شائع جدا)</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من نزيف (في اللثة، الأنف، الفم أو أي نزيف) لا يتوقف، أو بول محمر أو وردي، أو كدمات غير متوقعة (حيث قد يكون لديك صفائح دموية أقل من المعتاد وهو أمر شائع جدا).</p><p dir="RTL"><strong>الأعراض الجانبية المحتملة:</strong></p><p dir="RTL">&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">كجميع الادوية، قد يسبب بريكسيت أعراض جانبية على الرغم من أنها قد لا تحدث للجميع.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">قد تشمل الاعراض الجانبية من بريكسيت على:</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">شائع جدا: انخفاض خلايا الدم البيضاء، انخفاض مستوى الهيموجلوبين (فقر الدم)، انخفاض تعداد الصفائح الدموية، الإسهال، التقيؤ، الألم، الاحمرار، الانتفاخ أو قروح في فمك، الغثيان، فقدان الشهية، الارهاق، الطفح الجلدي، فقدان الشعر، الإمساك، فقدان الإحساس وفحوص الدم الغير طبيعية للكلى.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">شائع: ردود فعل تحسسية (طفح جلدي / الإحساس بالحرق أو الوخز)، العدوى، الحمى، الجفاف، الفشل الكلوي (هي الحالة حيث يزداد مستوى اليوريا في الدم ولم تعد الكلى تعمل بما فيه الكفاية مع أعراض الاستهلاك المفرط للمياه، التبول المتكرر)، تهيج الجلد والحكة، آلام في الصدر، ضعف العضلات، التهاب العين (التهاب الملتحمة)، اضطراب في المعدة، آلام في البطن، تغير حاسة الذوق، فحوص الدم الغير طبيعية للكبد، والعيون الدامعة.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">غير شائع: تسارع معدل ضربات القلب، التهاب بطانة المريء مع بريكسيت / العلاج الاشعة (حالة التهابية في المريء مع احساس بالحرقة)، التهاب بطانة الأمعاء الغليظة، والتي قد تكون مصحوبة بنزيف في الأمعاء أو المستقيم (التهاب القولون)، وتندب الأكياس الهوائية للرئة (التهاب رئوي خلالي)، السوائل الزائدة في أنسجة الجسم مما يسبب تورم (وذمة). بعض المرضى تعرضوا لسكتة دماغية أثناء تلقي بريكسيت عادة بالتزامن مع علاج آخر مضاد للسرطان.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">نادر: رد فعل سحب الاشعة، طفح جلدي مثل حروق الشمس الشديدة التي يمكن أن تحدث على الجلد الذي سبق أن تعرض للعلاج بالاشعة، من أيام إلى سنوات بعد التعرض للاشعة.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">قد يكون لديك أي من هذه الأعراض و / أو الحالات. يجب عليك إخبار طبيبك في أقرب وقت ممكن عندما تبدأ تعاني من أي من هذه الاعراض الجانبية.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">غير معروف: قد يحصل ندوب في الأكياس الهوائية للرئة المرتبطة بعلاج الاشعة (التهاب رئوي إشعاعي) في المرضى الذين&nbsp; تم علاجهم أيضا بالاشعة سابقا أو أثناء العلاج باستخدام بريكسيت، الألم في الذراعين والساقين، انخفاض في درجة الحرارة وتغير في اللون.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">تحدث مع طبيبك إذا كنت قلقا بشأن أي اعراض جانبية.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><em>إذا أصبحت إحدى الأعراض الجانبية خطيرة، أو إذا لاحظت أي أعراض جانبية غير مذكورة في النشرة، يرجى اعلام طبيبك أو الصيدلي.</em></p></td></tr></tbody></table></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><em>يحفظ بريكسيت بعيداً عن متناول و مرأى الأطفال و يحفظ في علبته.</em></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">لا تخزن القوارير الغير المفتوحة فوق 30 &deg;م.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">ينبغي استخدام محلول التشريب المخفف على الفور. عند إعدادها وفقا للتوجيهات، ينبغي أن يبقي محلول التشريب من بيميتريكسد المعاد حله والمخفف ما بين 2 &deg;م إلى 8 &deg;م لمدة 24 ساعة.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">للاستخدام مرة واحدة فقط. يجب التخلص من أي منتج طبي غير مستخدم أو مخلفات وفقا للمتطلبات المحلية.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>يستخدم وفقاً لتاريخ الانتهاء.</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><em>لا تستخدم بريكسيت بعد تاريخ الانتهاء المذكور على العلبة. يعود تاريخ الانتهاء الى اخر يوم في الشهر.</em></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><em>لا تستخدم بريكسيت إذا لاحظت أي عيب في المنتج و/أو علبته</em></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><em>يجب عدم التخلص من الأدوية عبر مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن طريقة التخلص من الأدوية الغير مطلوبة. هذه الإجراءات ستساعد على حماية البيئة.</em></p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong><em>المادة الفعالة</em></strong><strong>:</strong> تحتوي كل قارورة على 604.13 ملغم بيميتريكسد ثنائي الصوديوم هيميهيدريت خماسي كمسحوق ما يعادل 500 ملغم بيميتريكسد. بعد إعادة حله مع 20 مل (0.9٪) محلول كلوريد الصوديوم، يحتوي كل مل من المحلول الناتج على 25 ملغم بيميتريكسد.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong><em>المسوغات</em></strong><em>:</em> مانيتول، محلول هيدروكسيد الصوديوم ومحلول حمض الهيدروكلوريك لتعديل الأس الهيدروجيني.</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p><strong>ب.كيف يبدو بريكسيت وماهي محتويات العلبة:</strong></p><p>بريكسيت هو مسحوق مجفف بالتبريد في قارورة 50 مل زجاجية نوع <strong>&nbsp;</strong>Iعديمة اللون بسدادة مطاطية وغطاء ألومنيوم فتح علوي في شريط فاصل واقي، تحتوي على 500 ملغم بيميتريكسد<strong>.</strong></p><p>متوفر بحزمة من 1 قارورة مرفقة مع نشرة معلومات المريض.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">إم إن للمستحضرات الصيدلانية</p></td></tr><tr><td style="vertical-align:top"><p>Pak İş Merkezi, Prof. Dr. B&uuml;lent Tarcan Sok.,</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">اسطنبول No: 5/1, 34349 Gayrettepe/</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">تركيا</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">تليفون: 02123373800</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">فاكس: +90.212.337 38 01</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">بريد إالكتروني: info@mn.com.tr</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>المصنّع:</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">إم إن للمستحضرات الصيدلانية</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">سانايي شارع رقم: 66</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">ينيبوسنا - باهسيليفلر &ndash; اسطنبول</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">تركيا</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><em>لأي معلومات عن هذا المنتج الطبي، يرجى التواصل مع الوكيل المحلي لحامل ترخيص التسويق:</em></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">المملكة العربية السعودية</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">مؤسسة الصالحية التجارية.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">ص.ب. 991 الرياض 11421</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">تليفون: +966 11 464 6955</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">فاكس: +966 11 463 4362</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">موقع الكتروني: www.salehiya.com</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            آخر تاريخ لاعتماد هذه النشرة هو 12/2018، رقم الاصدار: 03
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                PREXET 500 mg powder for concentrate for solution for infusion.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each 50 ml vial contains:
Active substance: 604.13 mg pemetrexed disodium hemipentahydrate equivalent to 500 mg pemetrexed base. Following reconstitution (see section 6.6) each 50 ml vial contains 25 mg/ml pemetrexed.

Excipient(s):
Sodium hydroxide (sufficient quantity).
For the full list of the excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for concentrate for solution for infusion. 
Vial contains white to light yellow or yellow-green lyophilized powder.
Following reconstitution with 0.9% sodium chloride the solution is clear colorless-yellow or between yellow-green.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Malignant pleural mesothelioma</u></p><p>PREXET in combination with cisplatin is indicated for the treatment of chemotherapy naive patients with unresectable malignant pleural mesothelioma.</p><p><u>&nbsp;</u></p><p><u>Non-small cell lung cancer</u></p><p>Pemetrexed in combination with cisplatin is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) other than predominantly squamous cell histology (see section 5.1).</p><p>&nbsp;</p><p>Pemetrexed is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see section 5.1).</p><p>&nbsp;</p><p>Pemetrexed is indicated as monotherapy for the second-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PREXET must only be administered under the supervision of a physician qualified in the use of anti-cancer chemotherapy.</p><p><strong>&nbsp;</strong></p><p><strong>Posology/frequency and duration of administration:</strong></p><p>PREXET solution should be prepared according to instructions given in section 6.6.</p><p><u>&nbsp;</u></p><p><u>PREXET in combination with cisplatin:</u></p><p>The recommended dose of PREXET is 500 mg/m<sup>2</sup> of body surface area administered as an intravenous infusion over 10 minutes on the first day of each 21-day cycle. The recommended dose of cisplatin is 75 mg/m<sup>2 </sup>of body surface area infused over two hours approximately 30 minutes after completion of the pemetrexed infusion on the first day of each 21-day cycle. <u>Patients must receive adequate anti-emetic treatment and appropriate hydration prior to and/or after receiving cisplatin</u> (see also cisplatin Summary of Product Characteristics for specific dosing advice).</p><p><strong>&nbsp;</strong></p><p><u>PREXET as single agent:</u></p><p>In patients treated for non-squamous non-small cell lung cancer after prior chemotherapy, the recommended dose of PREXET is 500 mg/m<sup>2</sup> body surface area administered as an intravenous infusion over 10 minutes on the first day of each 21-day cycle.</p><p><strong>&nbsp;</strong></p><p><u>Pre-medication regimen:</u></p><p>To reduce the incidence and severity of skin reactions, a corticosteroid should be given the day prior to, on the day of, and the day after pemetrexed administration. The corticosteroid should be equivalent to 4 mg of dexamethasone administered orally twice a day (see section 4.4).</p><p>&nbsp;</p><p>Patients should be informed about usage of this product and the supportive vitamins.</p><p>&nbsp;</p><p><u>Monitoring:</u></p><p>Patients receiving pemetrexed should be monitored before each dose with a complete blood count, including a differential leukocyte and thrombocyte count. Prior to each chemotherapy administration, blood chemistry tests should be collected to evaluate renal and hepatic function. Before the start of any cycle of chemotherapy, patients are required to have the following:</p><p>&nbsp;</p><p>Absolute neutrophil count (ANC) should be &ge;1500 cells/mm<sup>3</sup> and platelets should be &ge;100000 cells/mm<sup>3</sup>.</p><p>Creatinine clearance should be &ge;45 ml/min.</p><p>&nbsp;</p><p>The total bilirubin should be &le;1.5-times upper limit of normal. Alkaline phosphatase (AP), aspartate aminotransferase (AST or SGOT), and alanine aminotransferase (ALT or SGPT) should be &le; 3-times upper limit of normal. Alkaline phosphatase, AST, and ALT &le;5-times upper limit of normal is acceptable if liver has tumor involvement.</p><p>&nbsp;</p><p><u>Dose adjustment:</u></p><p>Dose adjustments at the start of a subsequent cycle should be based on nadir hematologic counts or maximum non-hematologic toxicity from the preceding cycle of therapy. Treatment may be delayed to allow sufficient time for recovery. Upon recovery, patients should be re-treated using the guidelines in Tables 1, 2, and 3, which are applicable for PREXET used as a single agent or in combination with cisplatin.</p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>TABLE 1 &ndash; Dose modification table for PREXET (as single agent or in combination) and cisplatin &ndash; Hematologic toxicities</strong></p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:604px"><tbody><tr><td><p>Nadir ANC &lt; 500 /mm<sup>3</sup> and</p><p>nadir thrombocyte &ge;50,000/mm<sup>3</sup></p></td><td><p>75% of previous dose (both PREXET and cisplatin)</p></td></tr><tr><td><p>Nadir thrombocyte &le;50,000/mm<sup>3</sup> regardless of nadir ANC</p></td><td><p>75% of previous dose (both PREXET and cisplatin)</p></td></tr><tr><td><p>Nadir thrombocyte &lt;50,000/mm<sup>3</sup> with bleeding<sup>a</sup>, regardless of nadir ANC</p></td><td><p>50% of previous dose (both PREXET and cisplatin)</p></td></tr></tbody></table><p>Abbreviations: ANC: Absolute neutrophil count</p><p><sup>a </sup>These criteria meet the National Cancer Institute Common Toxicity Criteria (CTC v2.0; NCI 1998) definition of &ge;CTC Grade 2 bleeding.</p><p>&nbsp;</p><p>If patients develop non-hematologic toxicities &ge;Grade 3 (excluding neurotoxicity), PREXET should be withheld until resolution to less than or equal to the patient&#39;s pre-therapy value. Treatment should be resumed according to the guidelines in Table 2.</p><p><strong>&nbsp;</strong></p><p><strong>TABLE 2 - Dose modification table for PREXET (as single agent or in combination) and cisplatin - Non-Hematologic Toxicities </strong><sup>a, b</sup></p><p><strong><sup>&nbsp;</sup></strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:609px"><tbody><tr><td><p>&nbsp;</p></td><td><p><strong>Dose of Pemetrexed</strong></p><p><strong>(mg/m<sup>2</sup>)</strong></p></td><td><p><strong>Dose of Cisplatin</strong></p><p><strong>(mg/m<sup>2</sup>)</strong></p></td></tr><tr><td><p>Any Grade 3 or 4 toxicities except mucositis</p></td><td><p>75% of previous dose</p></td><td><p>75% of previous dose</p></td></tr><tr><td><p>Any diarrhea requiring hospitalization (irrespective of grade) or Grade 3 or 4 diarrhea</p></td><td><p>75% of previous dose</p></td><td><p>75% of previous dose</p></td></tr><tr><td><p>Grade 3 or 4 mucositis</p></td><td><p>50% of previous dose</p></td><td><p>100% of previous dose</p></td></tr></tbody></table><p><sup>a</sup> National Cancer Institute Common Toxicity Criteria (CTC v2.0; NCI 1998)</p><p><sup>b</sup> Excluding neurotoxicity</p><p>&nbsp;</p><p>In the event of neurotoxicity, the recommended dose adjustment for PREXET and cisplatin is documented in Table 3. Patients should discontinue therapy if Grade 3 or 4 neurotoxicity is observed.</p><p>&nbsp;</p><p><strong>TABLE 3 - Dose modification table for PREXET (as single agent or in combination) and cisplatin &ndash; Neurotoxicity</strong></p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:614px"><tbody><tr><td><p><strong>CTC<sup>a</sup> Grade</strong></p></td><td><p><strong>Dose of Pemetrexed (mg/m<sup>2</sup>)</strong></p></td><td><p><strong>Dose of Cisplatin (mg/m<sup>2</sup>)</strong></p></td></tr><tr><td><p>0 &ndash; 1</p></td><td><p>100% of previous dose</p></td><td><p>100% of previous dose</p></td></tr><tr><td><p>2</p></td><td><p>100% of previous dose</p></td><td><p>50% of previous dose</p></td></tr></tbody></table><p><sup>a</sup> National Cancer Institute Common Toxicity Criteria (CTC v2.0; NCI 1998)</p><p>&nbsp;</p><p>Treatment with PREXET should be discontinued if a patient experiences any hematologic or non-hematologic Grade 3 or 4 toxicity after 2 dose reductions or immediately if Grade 3 or 4 neurotoxicity is observed.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Additional information on special populations:</strong></p><p><strong>&nbsp;</strong></p><p><strong>Renal impairment: </strong></p><p>(Standard Cockcroft and Gault formula or Glomerular Filtration Rate measured Tc99m-DPTA serum clearance method): Pemetrexed is primarily eliminated unchanged by renal excretion. In clinical studies, patients with creatinine clearance of &ge;45 ml/min required no dose adjustments other than those recommended for all patients. There are insufficient data on the use of pemetrexed in patients with creatinine clearance below 45 ml/min; therefore, the use of pemetrexed is not recommended (see section 4.4).</p><p><strong>&nbsp;</strong></p><p><strong>Hepatic impairment:</strong></p><p>No relationships between AST (SGOT), ALT (SGPT), or total bilirubin and pemetrexed pharmacokinetics were identified. However, patients with hepatic impairment, such as bilirubin &gt;1.5-times the upper limit of normal and/or aminotransferase &gt;3.0-times the upper limit of normal (hepatic metastases absent) or &gt;5.0-times the upper limit of normal (hepatic metastases present), have not been specifically studied.</p><p><strong>&nbsp;</strong></p><p><strong>Pediatric population:</strong></p><p>Since safety and efficacy have not been investigated in this patient group, use of PREXET in patients less than 18 years of age is not recommended.</p><p><strong>&nbsp;</strong></p><p><strong>Geriatric population:</strong></p><p>In clinical studies, there has been no indication that patients 65 years of age or older are at increased risk of adverse events compared to patients younger than 65 years old. No dose reductions other than those recommended for all patients are necessary.</p><p style="text-indent:50px"><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                It is contraindicated in patients with a known hypersensitivity to pemetrexed or to any of the excipients.

Breast-feeding should be discontinued during treatment with pemetrexed (see section 4.6).

Concomitant use with yellow fever vaccine is contraindicated (see section 4.5).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pemetrexed can suppress bone marrow function as manifested by neutropenia, thrombocytopenia, and anemia (or pancytopenia) (see section 4.8). Myelosuppression is usually the dose-limiting toxicity. Patients should be monitored for myelosuppression during therapy and pemetrexed should not be given to patients until absolute neutrophil count (ANC) returns to &ge;1,500 cells/mm<sup>3</sup> and platelet count returns to &ge;100,000 cells/mm<sup>3</sup>. Dose reductions for subsequent cycles are based on nadir ANC, platelet count, and maximum non-hematologic toxicity seen from the previous cycle (see section 4.2).</p><p>&nbsp;</p><p>Skin reactions have been reported in patients not pre-treated with a corticosteroid. Pre-treatment with dexamethasone (or equivalent) can reduce the incidence and severity of skin reactions (see section 4.2).</p><p>&nbsp;</p><p>An insufficient number of patients has been studied with creatinine clearance of below 45 ml/min. Therefore, the use of pemetrexed in patients with creatinine clearance of &lt;45 ml/min is not recommended (see section 4.2).</p><p>&nbsp;</p><p>Patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 ml/min) should avoid taking non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, and acetylsalicylic acid (&gt;1.3 g daily) for 2 days before, on the day of, and 2 days following pemetrexed administration (see section 4.5).</p><p>&nbsp;</p><p>In patients with mild to moderate renal insufficiency eligible for pemetrexed therapy, NSAIDs with long elimination half-lives should be interrupted for at least 5 days prior to, on the day of, and at least 2 days following pemetrexed administration (see section 4.5).</p><p>&nbsp;</p><p>Serious renal events, including acute renal failure, have been reported with pemetrexed alone or in association with other chemotherapeutic agents. Many of the patients in whom these occurred had underlying risk factors for the development of renal events, including dehydration or pre-existing hypertension or diabetes.</p><p>&nbsp;</p><p>The effect of body space fluid, such as pleural effusion or ascites, on pemetrexed is not fully defined. In patients with clinically significant body space fluid, drainage of body space fluid collection prior to pemetrexed treatment should be considered.</p><p>&nbsp;</p><p>Due to the gastrointestinal toxicity of pemetrexed given in combination with cisplatin, severe dehydration has been observed. Therefore, patients should receive adequate anti-emetic treatment and appropriate hydration prior to and/or after receiving treatment.</p><p>&nbsp;</p><p>Serious cardiovascular events, including myocardial infarction and cerebrovascular events have been uncommonly reported during clinical studies with pemetrexed, usually when given in combination with another cytotoxic agent. Most of the patients in whom these events have been observed had pre-existing cardiovascular risk factors (see section 4.8).</p><p>&nbsp;</p><p>Immuno-depressed status is common in cancer patients. As a result, concomitant use of live attenuated vaccines is not recommended (see section 4.3 and 4.5).</p><p>&nbsp;</p><p>Pemetrexed can have genetically damaging effects. Sexually mature males are advised not to father a child during the treatment and up to 6 months thereafter. Contraceptive measures or abstinence are recommended. Owing to the possibility of pemetrexed treatment causing irreversible infertility, men are advised to seek counseling on sperm storage before starting treatment.</p><p>&nbsp;</p><p>Women of childbearing potential must use effective contraception during treatment with pemetrexed (see section 4.6).</p><p>&nbsp;</p><p>Cases of radiation pneumonitis have been reported in patients treated with radiation either prior, during, or subsequent to their pemetrexed therapy. Particular attention should be paid to these patients, and caution exercised with use of other radio-sensitizing agents.</p><p>&nbsp;</p><p>Cases of radiation recall have been reported in patients who received radiotherapy weeks or years previously.</p><p>&nbsp;</p><p>This medicinal product contains approximately 54 mg of sodium per vial. To be taken into consideration by patients on a controlled sodium diet.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pemetrexed is mainly eliminated unchanged renally by tubular secretion and to a lesser extent by glomerular filtration. Concomitant administration of nephrotoxic drugs (e.g., aminoglycoside, loop diuretics, platinum compounds, cyclosporine) could potentially result in delayed clearance of pemetrexed. This combination should be used with caution. If necessary, creatinine clearance should be closely monitored.</p><p>&nbsp;</p><p>Concomitant administration of substances that are also tubularly secreted (e.g., probenecid, penicillin) could potentially result in delayed clearance of pemetrexed. Caution should be made when these drugs are combined with pemetrexed. If necessary, creatinine clearance should be closely monitored.</p><p>&nbsp;</p><p>In patients with normal renal function (creatinine clearance &ge;80 ml/min), high doses of non-steroidal anti-inflammatory drugs (NSAIDs, such as ibuprofen &gt; 1600 mg/day) and acetylsalicylic acid at higher doses (&ge;1.3 g daily) may decrease pemetrexed elimination and, consequently, increase the occurrence of pemetrexed adverse events. Therefore, caution should be made when administering higher doses of NSAIDs or acetylsalicylic acid, concurrently with pemetrexed to patients with normal function (creatinine clearance &ge;80 ml/min).</p><p>&nbsp;</p><p>In patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 ml/min), the concomitant administration of pemetrexed with NSAIDs (e.g., ibuprofen) or acetylsalicylic acid at higher doses should be avoided for 2 days before, on the day of, and 2 days following pemetrexed administration (see section 4.4).&nbsp;</p><p>&nbsp;</p><p>In the absence of data regarding potential interaction with NSAIDs having longer half-lives such as piroxicam or rofecoxib, the concomitant administration with pemetrexed in patients with mild to moderate renal insufficiency should be interrupted for at least 5 days prior to, on the day of, and at least 2 days following pemetrexed administration (see section 4.4).</p><p>&nbsp;</p><p>Pemetrexed undergoes limited hepatic metabolism. Results from <em>in vitro</em> studies with human liver microsomes indicated that pemetrexed would not be predicted to cause clinically significant inhibition of the metabolic clearance of drugs metabolized by CYP3A, CYP2D6, CYP2C9, and CYP1A2.</p><p><u>&nbsp;</u></p><p>Interactions common to all cytotoxics:</p><p>Due to the increased thrombotic risk in patients with cancer, the use of anticoagulation treatment is frequent. The high intra-individual variability of the coagulation status during diseases and the possibility of interaction between oral anticoagulants and anti-cancer chemotherapy require increased frequency of INR (International Normalized Ratio) monitoring, if it is decided to treat the patient with oral anticoagulants.</p><p><u>&nbsp;</u></p><p>Contraindicated concomitant use: Yellow fever vaccine: Risk of fatal generalized vaccinale disease (see section 4.3).</p><p><u>&nbsp;</u></p><p>Concomitant use, not recommended: Live attenuated vaccines (except yellow fever, for which concomitant use is contraindicated):<em> </em>Risk of systemic, possibly fatal, disease. The risk is increased in subjects who are already immunosuppressed by their underlying disease. Use an inactivated vaccine where it exists (poliomyelitis) (see section 4.4).</p><p>&nbsp;</p><p><strong>Additional information on special populations:</strong></p><p><strong>&nbsp;</strong></p><p><strong>Pediatric population:</strong></p><p>No interaction studies have been performed.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>General advice:</strong></p><p>Pregnancy Category: D</p><p><strong>&nbsp;</strong></p><p><strong>Contraception in males and females</strong></p><p>Women of childbearing potential must use effective contraception during treatment with pemetrexed. Pemetrexed can have genetically damaging effects. Sexually mature males are advised not to father a child during the treatment, and up to 6 months thereafter. Contraceptive measures or abstinence are recommended.</p><p>&nbsp;</p><p><strong>Pregnancy</strong></p><p>Pemetrexed has harmful pharmacological effects on pregnancy and/or the fetus/newborn child. PREXET should not be used during pregnancy unless clearly necessary, after a careful consideration of the needs of the mother and the risk for the fetus (see section 4.4).</p><p><strong>&nbsp;</strong></p><p><strong>Lactation</strong></p><p>There is insufficient information on the excretion of pemetrexed in human or animal breast milk. Physicochemical and available pharmacodynamic/toxicological data on pemetrexed point to excretion in breast milk and a risk to the suckling child cannot be excluded. PREXET should not be used during breast-feeding (see section 4.3).</p><p><strong>&nbsp;</strong></p><p><strong>Fertility</strong></p><p>Animal studies have shown reproductive toxicity (see section 5.3). Pemetrexed can have genetically damaging effects. Sexually mature males are advised not to father a child during the treatment and up to 6 months thereafter.</p><p>&nbsp;</p><p>Contraceptive measures or abstinence are recommended. Owing to the possibility of pemetrexed treatment causing irreversible infertility, men are advised to seek counseling on sperm storage before starting treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects of pemetrexed on the ability to drive and use machines have been performed. However, it has been reported that pemetrexed may cause fatigue. Therefore patients should be cautioned against driving or operating if this event occurs.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>a. Summary of the safety profile</strong></p><p>The most commonly reported undesirable effects related to pemetrexed, whether used as monotherapy or in combination, are bone marrow suppression manifested as anaemia, neutropenia, leukopenia, thrombocytopenia; and gastrointestinal toxicities, manifested as anorexia, nausea, vomiting, diarrhoea, constipation, pharyngitis, mucositis, and stomatitis. Other undesirable effects include renal toxicities, increased aminotransferases, alopecia, fatigue, dehydration, rash, infection/sepsis and neuropathy. Rarely seen events include Stevens-Johnson syndrome and Toxic epidermal necrolysis.</p><p><strong>&nbsp;</strong></p><p><strong>b. Tabulated summary of adverse reactions</strong></p><p>Adverse reactions:</p><p>Frequency estimate: Very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100), rare ((&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000), unknown (cannot be estimated from available data).</p><p>&nbsp;</p><p>Within each frequency grouping, undesirable effects are presented in order to decreasing seriousness.</p><p><strong>&nbsp;</strong></p><p><strong>Mesothelioma study:</strong></p><p>The table below provides the frequency and severity of undesirable effects that have been reported in &lt;5% of 168 patients with Mesothelioma who were randomized to receive cisplatin and pemetrexed and 163 patients with Mesothelioma to receive single agent cisplatin.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="3">&nbsp;<p><strong>System organ </strong></p><p><strong>class</strong></p></td><td rowspan="3"><p><strong>Frequency</strong></p></td><td rowspan="3"><p><strong>Event*</strong></p></td><td colspan="2"><p><strong>Pemetrexed / Cisplatin</strong></p></td><td colspan="2"><p><strong>Cisplatin</strong></p></td></tr><tr><td colspan="2"><p><strong>(N=168)</strong></p></td><td colspan="2"><p><strong>(N=163)</strong></p></td></tr><tr><td><p><strong>All grades toxicity (%)</strong></p></td><td><p><strong>Grade</strong></p><p><strong>3-4 toxicity (%)</strong></p></td><td><p><strong>All grades toxicity (%)</strong></p></td><td><p><strong>Grade</strong></p><p><strong>3-4 toxicity (%)</strong></p></td></tr><tr><td rowspan="4"><p>Blood and lymphatic system disorders</p></td><td rowspan="4"><p>Very common</p></td><td><p>Neutrophils/</p><p>Granulocytes decreased</p></td><td><p>56.0</p></td><td><p>23.2</p></td><td><p>13.5</p></td><td><p>3.1</p></td></tr><tr><td><p>Leukocytes decreased</p></td><td><p>53.0</p></td><td><p>14.9</p></td><td><p>16.6</p></td><td><p>0.6</p></td></tr><tr><td><p>Hemoglobin decreased</p></td><td><p>26.2</p></td><td><p>4.2</p></td><td><p>10.4</p></td><td><p>0.0</p></td></tr><tr><td><p>Thrombocyte decreased</p></td><td><p>23.2</p></td><td><p>5.4</p></td><td><p>8.6</p></td><td><p>0.0</p></td></tr><tr><td><p>Metabolism and nutrition disorders</p></td><td><p>Common</p></td><td><p>Dehydration</p></td><td><p>6.5</p></td><td><p>4.2</p></td><td><p>0.6</p></td><td><p>0.6</p></td></tr><tr><td rowspan="2"><p>Nervous system disorders</p></td><td><p>Very common</p></td><td><p>Neuropathy-Sensory</p></td><td><p>10.1</p></td><td><p>0.0</p></td><td><p>9.8</p></td><td><p>0.6</p></td></tr><tr><td><p>Common</p></td><td><p>Taste disturbance</p></td><td><p>7.7</p></td><td><p>0.0***</p></td><td><p>6.1</p></td><td><p>0.0***</p></td></tr><tr><td><p>Eye disorders</p></td><td><p>Common</p></td><td><p>Conjunctivitis</p></td><td><p>5.4</p></td><td><p>0.0</p></td><td><p>0.6</p></td><td><p>0.0</p></td></tr><tr><td rowspan="7"><p>Gastrointestinal disorders</p></td><td rowspan="6"><p>Very common</p></td><td><p>Diarrhea</p></td><td><p>16.7</p></td><td><p>3.6</p></td><td><p>8.0</p></td><td><p>0.0</p></td></tr><tr><td><p>Vomiting</p></td><td><p>56.5</p></td><td><p>10.7</p></td><td><p>49.7</p></td><td><p>4.3</p></td></tr><tr><td><p>Stomatitis/Pharyngitis</p></td><td><p>23.2</p></td><td><p>3.0</p></td><td><p>6.1</p></td><td><p>0.0</p></td></tr><tr><td><p>Nausea</p></td><td><p>82.1</p></td><td><p>11.9</p></td><td><p>76.7</p></td><td><p>5.5</p></td></tr><tr><td><p>Anorexia</p></td><td><p>20.2</p></td><td><p>1.2</p></td><td><p>14.1</p></td><td><p>0.6</p></td></tr><tr><td><p>Constipation</p></td><td><p>11.9</p></td><td><p>0.6</p></td><td><p>7.4</p></td><td><p>0.6</p></td></tr><tr><td><p>Common</p></td><td><p>Dyspepsia</p></td><td><p>5.4</p></td><td><p>0.6</p></td><td><p>0.6</p></td><td><p>0.0</p></td></tr><tr><td rowspan="2"><p>Skin and subcutaneous tissue disorders</p></td><td rowspan="2"><p>Very common</p></td><td><p>Rash</p></td><td><p>16.1</p></td><td><p>0.6</p></td><td><p>4.9</p></td><td><p>0.0</p></td></tr><tr><td><p>Alopecia</p></td><td><p>11.3</p></td><td><p>0.0***</p></td><td><p>5.5</p></td><td><p>0.0***</p></td></tr><tr><td rowspan="2"><p>Renal and urinary disorders</p></td><td rowspan="2"><p>Very common</p></td><td><p>Creatinine elevation</p></td><td><p>10.7</p></td><td><p>0.6</p></td><td><p>9.8</p></td><td><p>1.2</p></td></tr><tr><td><p>Creatinine clearance decreased**</p></td><td><p>16.1</p></td><td><p>0.6</p></td><td><p>17.8</p></td><td><p>1.8</p></td></tr><tr><td><p>General disorders and administration site conditions</p></td><td><p>Very common</p></td><td><p>Fatigue</p></td><td><p>47.6</p></td><td><p>10.1</p></td><td><p>42.3</p></td><td><p>9.2</p></td></tr></tbody></table><p>*Refer to National Cancer Institute CTC version 2 for each grade of toxicity except the term &ldquo;creatinine clearance ** decreased&rdquo;</p><p>** which is derived from the term &ldquo;renal/genitourinary other&rdquo;.</p><p>*** According to National Cancer Institute CTC (v2.0; NCI 1998), taste disturbance and alopecia should only be reported as Grade 1 or 2.</p><p>&nbsp;</p><p>Clinically relevant Common Toxicity Criteria (CTC) toxicities that were reported in &ge;1% and &le;5% of the patients that were randomly assigned to receive cisplatin and pemetrexed include: Renal failure, infection, pyrexia, febrile neutropenia, increased AST, ALT and GGT, urticaria and chest pain.</p><p>&nbsp;</p><p>Clinically relevant CTC toxicities that were reported in &lt;1% of the patients that were randomly assigned to receive cisplatin and pemetrexed include arrhythmia and motor neuropathy.</p><p>&nbsp;</p><p><strong>Second-line study:</strong></p><p>The table below provides the frequency and severity of undesirable effects that have been reported in &gt;5% of 265 patients randomly assigned to receive single agent pemetrexed and in &gt;5% of 276 patients randomly assigned to receive single agent docetaxel. All patients were diagnosed with locally advanced or metastatic non-small cell lung cancer and received prior chemotherapy.</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2"><p><strong>System organ class</strong></p></td><td rowspan="2"><p><strong>Frequency</strong></p></td><td rowspan="2"><p><strong>Event*</strong></p></td><td colspan="2"><p><strong>Pemetrexed</strong></p><p><strong>N=265</strong></p></td><td colspan="2"><p><strong>Docetaxel</strong></p><p><strong>N=276</strong></p></td></tr><tr><td><p><strong>All grades toxicity (%)</strong></p></td><td><p><strong>Grade</strong></p><p><strong>3-4 toxicity (%)</strong></p></td><td><p><strong>All grades toxicity (%)</strong></p></td><td><p><strong>Grade</strong></p><p><strong>3-4 toxicity (%)</strong></p></td></tr><tr><td rowspan="4"><p>Blood and lymphatic system disorders</p></td><td rowspan="3"><p>Very common</p></td><td><p>Neutrophils/ Granulocytes decreased</p></td><td><p>10.9</p></td><td><p>5.3</p></td><td><p>45.3</p></td><td><p>40.2</p></td></tr><tr><td><p>Leukocytes decreased</p></td><td><p>12.1</p></td><td><p>4.2</p></td><td><p>34.1</p></td><td><p>27.2</p></td></tr><tr><td><p>Hemoglobin decreased</p></td><td><p>19.2</p></td><td><p>4.2</p></td><td><p>22.1</p></td><td><p>4.3</p></td></tr><tr><td><p>Common</p></td><td><p>Thrombocyte decreased</p></td><td><p>8.3</p></td><td><p>1.9</p></td><td><p>1.1</p></td><td><p>0.4</p></td></tr><tr><td rowspan="6"><p>Gastrointestinal disorders</p></td><td rowspan="5"><p>Very common</p></td><td><p>Diarrhea</p></td><td><p>12.8</p></td><td><p>0.4</p></td><td><p>24.3</p></td><td><p>2.5</p></td></tr><tr><td><p>Vomiting</p></td><td><p>16.2</p></td><td><p>1.5</p></td><td><p>12.0</p></td><td><p>1.1</p></td></tr><tr><td><p>Stomatitis/Pharyngitis</p></td><td><p>14.7</p></td><td><p>1.1</p></td><td><p>17.4</p></td><td><p>1.1</p></td></tr><tr><td><p>Nausea</p></td><td><p>30.9</p></td><td><p>2.6</p></td><td><p>16.7</p></td><td><p>1.8</p></td></tr><tr><td><p>Anorexia</p></td><td><p>21.9</p></td><td><p>1.9</p></td><td><p>23.9</p></td><td><p>2.5</p></td></tr><tr><td><p>Common</p></td><td><p>Constipation</p></td><td><p>5.7</p></td><td><p>0.0</p></td><td><p>4.0</p></td><td><p>0.0</p></td></tr><tr><td rowspan="2"><p>Hepatobiliary disorders</p></td><td rowspan="2"><p>Common</p></td><td><p>SGPT (ALT)</p><p>elevation</p></td><td><p>7.9</p></td><td><p>1.9</p></td><td><p>1.4</p></td><td><p>0.0</p></td></tr><tr><td><p>SGOT (AST)</p><p>elevation</p></td><td><p>6.8</p></td><td><p>1.1</p></td><td><p>0.7</p></td><td><p>0.0</p></td></tr><tr><td rowspan="3"><p>Skin and subcutaneous tissue disorders</p></td><td><p>Very common</p></td><td><p>Rash /</p><p>desquamation</p></td><td><p>14.0</p></td><td><p>0.0</p></td><td><p>6.2</p></td><td><p>0.0</p></td></tr><tr><td rowspan="2"><p>Common</p></td><td><p>Pruritus</p></td><td><p>6.8</p></td><td><p>0.4</p></td><td><p>1.8</p></td><td><p>0.0</p></td></tr><tr><td><p>Alopecia</p></td><td><p>6.4</p></td><td><p>0.4**</p></td><td><p>37.7</p></td><td><p>2.2**</p></td></tr><tr><td rowspan="2"><p>General disorders and administration site conditions</p></td><td><p>Very common</p></td><td><p>Fatigue</p></td><td><p>34.0</p></td><td><p>5.3</p></td><td><p>35.9</p></td><td><p>5.4</p></td></tr><tr><td><p>Common</p></td><td><p>Fever</p></td><td><p>8.3</p></td><td><p>0.0</p></td><td><p>7.6</p></td><td><p>0.0</p></td></tr></tbody></table><p>*Refer to National Cancer Institute CTC version 2 for each grade of toxicity.</p><p>&nbsp;**According to National Cancer Institute CTC (v2.0; NCI 1998), alopecia should only be reported as Grade 1 or 2.</p><p>&nbsp;</p><p>Clinically relevant Common Toxicity Criteria (CTC) toxicities that were reported in &ge;1% and &lt;5% of the patients that were randomly assigned to pemetrexed include: Infection without neutropenia, febrile neutropenia, allergic reaction/hypersensitivity, increased creatinine, motor neuropathy, sensory neuropathy, erythema multiforme, and abdominal pain.</p><p>&nbsp;</p><p>Clinically relevant CTC toxicities that were reported in &lt;1% of the patients that were randomly assigned to pemetrexed include supraventricular arrhythmias.</p><p>&nbsp;</p><p>Clinically relevant Grade 3 and Grade 4 laboratory toxicities were similar between integrated Phase 2 results from three single agent pemetrexed studies (n=164) and the Phase 3 single agent pemetrexed study described above, with the exception of neutropenia (12.8% versus 5.3%, respectively) and alanine aminotransferase elevation (15.2% versus 1.9%, respectively). These differences were likely due to differences in the patient population, since the Phase 2 studies included both chemonaive and heavily pre-treated breast cancer patients with pre-existing liver metastases and/or abnormal baseline liver function tests.</p><p>&nbsp;</p><p><strong>First-line study:</strong></p><p>The table below provides the frequency and severity of undesirable effects considered possibly related to study drug that have been reported in &lt;5% of 839 patients with non-small cell lung cancer who were randomized to receive cisplatin and pemetrexed and 830 patients with non-small cell lung cancer who were randomized to receive cisplatin and gemcitabine. All patients received study therapy as initial treatment for locally advanced or metastatic non-small cell lung cancer.</p><table border="1" cellspacing="0" cellpadding="0" align="left" style="width:669px"><tbody><tr><td rowspan="3"><p><strong>System organ class</strong></p></td><td rowspan="3"><p><strong>Frequency</strong></p></td><td rowspan="3"><p><strong>Event**</strong></p></td><td colspan="2"><p><strong>Pemetrexed/Cisplatin</strong></p></td><td colspan="2"><p><strong>Gemcitabine/Cisplatin</strong></p></td></tr><tr><td colspan="2"><p><strong>(N=839)</strong></p></td><td colspan="2"><p><strong>(N=830)</strong></p></td></tr><tr><td><p><strong>All grades toxicity</strong></p><p><strong>&nbsp;(%)</strong></p></td><td><p><strong>Grade 3-4 toxicity (%)</strong></p></td><td><p><strong>All grades toxicity </strong></p><p><strong>(%)</strong></p></td><td><p><strong>Grade 3-4 toxicity (%)</strong></p></td></tr><tr><td rowspan="4"><p>Blood and lymphatic system disorders</p></td><td rowspan="4"><p>Very common</p></td><td><p>Hemoglobin decreased</p></td><td><p>33.0*</p></td><td><p>5.6*</p></td><td><p>45.7*</p></td><td><p>9.9*</p></td></tr><tr><td><p>Neutrophils/</p><p>Granulocytes decreased</p></td><td><p>29.0*</p></td><td><p>15.1*</p></td><td><p>38.4*</p></td><td><p>26.7*</p></td></tr><tr><td><p>Leukocyte decreased</p></td><td><p>17.8</p></td><td><p>4.8*</p></td><td><p>20.6</p></td><td><p>7.6*</p></td></tr><tr><td><p>Thrombocyte decreased</p></td><td><p>10.1*</p></td><td><p>4.1*</p></td><td><p>26.6*</p></td><td><p>12.7*</p></td></tr><tr><td rowspan="2"><p>Nervous system disorders</p></td><td rowspan="2"><p>Common</p></td><td><p>Neuropathy-Sensory</p></td><td><p>8.5*</p></td><td><p>0.0*</p></td><td><p>12.4*</p></td><td><p>0.6*</p></td></tr><tr><td><p>Taste disturbance</p></td><td><p>8.1</p></td><td><p>0.0***</p></td><td><p>8.9</p></td><td><p>0.0***</p></td></tr><tr><td rowspan="7"><p>Gastrointestinal disorders</p></td><td rowspan="6"><p>Very common</p></td><td><p>Nausea</p></td><td><p>56.1</p></td><td><p>7.2*</p></td><td><p>53.4</p></td><td><p>3.9*</p></td></tr><tr><td><p>Vomiting</p></td><td><p>39.7</p></td><td><p>6.1</p></td><td><p>35.5</p></td><td><p>6.1</p></td></tr><tr><td><p>Anorexia</p></td><td><p>26.6</p></td><td><p>2.4*</p></td><td><p>24.2</p></td><td><p>0.7*</p></td></tr><tr><td><p>Constipation</p></td><td><p>21.0</p></td><td><p>0.8</p></td><td><p>19.5</p></td><td><p>0.4</p></td></tr><tr><td><p>Stomatitis/Pharyngitis</p></td><td><p>13.5</p></td><td><p>0.8</p></td><td><p>12.4</p></td><td><p>0.1</p></td></tr><tr><td><p>Diarrhea without colostomy</p></td><td><p>12.4</p></td><td><p>1.3</p></td><td><p>12.8</p></td><td><p>1.6</p></td></tr><tr><td><p>Common</p></td><td><p>Dyspepsia/heartburn</p></td><td><p>5.2</p></td><td><p>0.1</p></td><td><p>5.9</p></td><td><p>0.0</p></td></tr><tr><td rowspan="2"><p>Skin and subcutaneous tissue disorders</p></td><td><p>Very common</p></td><td><p>Alopecia</p></td><td><p>11.9*</p></td><td><p>0***</p></td><td><p>21.4*</p></td><td><p>0.5***</p></td></tr><tr><td><p>Common</p></td><td><p>Rash / desquamation</p></td><td><p>6.6</p></td><td><p>0.1</p></td><td><p>8.0</p></td><td><p>0.5</p></td></tr><tr><td><p>Renal and urinary disorders</p></td><td><p>Very common</p></td><td><p>Creatinine</p></td><td><p>10.1*</p></td><td><p>0.8</p></td><td><p>6.9*</p></td><td><p>0.5</p></td></tr><tr><td><p>General disorders and administration site conditions</p></td><td><p>Very common</p></td><td><p>Fatigue</p></td><td><p>42.7</p></td><td><p>6.7</p></td><td><p>44.9</p></td><td><p>4.9</p></td></tr></tbody></table><p>&nbsp;* P-values &lt;0.05 comparing pemetrexed/cisplatin to gemcitabine/cisplatin, using Fisher Exact test.</p><p>&nbsp;**Refer to National Cancer Institute Common Toxicity Criteria (CTC) (v2.0; NCI 1998) for each Grade of Toxicity.</p><p>&nbsp;***According to National Cancer Institute Common Toxicity Criteria (CTC) (v2.0; NCI 1998), taste disturbance and alopecia should only be reported as Grade 1 or 2.</p><p>&nbsp;</p><p><strong>c. Description of selected adverse reactions</strong></p><p>Clinically relevant toxicity that was reported in &ge;1% and &le;5% of the patients that were randomly assigned to receive cisplatin and pemetrexed include: AST increase, ALT increase, infection, febrile neutropenia, renal failure, pyrexia, dehydration, conjunctivitis, and creatinine clearance decrease.</p><p>&nbsp;</p><p>Clinically relevant toxicity that was reported in &le;1% of the patients that were randomly assigned to receive cisplatin and pemetrexed include: GGT increase, chest pain, arrhythmia, and motor neuropathy.</p><p>&nbsp;</p><p>Clinically relevant toxicities with respect to gender were similar to the overall population in patients receiving pemetrexed plus cisplatin.</p><p>&nbsp;</p><p>Cardiovascular and cerebrovascular events, including myocardial infarction, angina pectoris, cerebrovascular accident and transient ischemic attack have been uncommonly reported during clinical studies with pemetrexed, usually when given in combination with another cytotoxic agent. Most of the patients in whom these events have been observed had pre-existing cardiovascular risk factors.</p><p>&nbsp;</p><p>Rare cases of hepatitis, potentially serious, have been reported during clinical studies with pemetrexed.</p><p>&nbsp;</p><p>Pancytopenia has been uncommonly reported during clinical trials with pemetrexed.</p><p>&nbsp;</p><p>In clinical trials, cases of colitis (including intestinal and rectal bleeding, intestinal perforation, intestinal necrosis and typhlitis) have been reported uncommonly in patients treated with pemetrexed.</p><p>&nbsp;</p><p>In clinical trials, cases of interstitial pneumonitis with respiratory insufficiency, sometimes fatal, have been reported uncommonly in patients treated with pemetrexed.</p><p>&nbsp;</p><p>Uncommon cases of edema have been reported in patients treated with pemetrexed.</p><p>&nbsp;</p><p>Esophagitis/ radiation esophagitis has been uncommonly reported during clinical trials with pemetrexed.</p><p>&nbsp;</p><p>During post marketing surveillance, the following adverse reactions have been reported in patients treated with pemetrexed:</p><p>&nbsp;</p><p>Cases of acute renal failure have been reported with pemetrexed alone or in association with other chemotherapeutic agents (see section 4.4).</p><p>&nbsp;</p><p>Cases of radiation pneumonitis have been reported in patients treated with radiation either prior, during or subsequent to their pemetrexed therapy (see section 4.4).</p><p>&nbsp;</p><p>Cases of radiation recall have been reported in patients who have received radiotherapy previously (see section 4.4).</p><p>&nbsp;</p><p>Cases of peripheral ischemia leading to extremity necrosis have been reported.</p><p><strong>&nbsp;</strong></p><p><strong>e. Other special populations</strong></p><p><strong>Renal impairment: </strong></p><p>(Standard Cockcroft and Gault formula or Glomerular Filtration Rate measured Tc99m-DPTA serum clearance method): Pemetrexed is primarily eliminated unchanged by renal excretion. In clinical studies, patients with creatinine clearance of &ge;45 ml/min required no dose adjustments other than those recommended for all patients. There are insufficient data on the use of pemetrexed in patients with creatinine clearance below 45 ml/min; therefore, the use of pemetrexed is not recommended (see section 4.4).</p><p><strong>&nbsp;</strong></p><p><strong>Hepatic impairment:</strong></p><p>No relationships between AST (SGOT), ALT (SGPT), or total bilirubin and pemetrexed pharmacokinetics were identified. However, patients with hepatic impairment, such as bilirubin &gt;1.5-times the upper limit of normal and/or aminotransferase &gt;3.0-times the upper limit of normal (hepatic metastases absent) or &gt;5.0-times the upper limit of normal (hepatic metastases present), have not been specifically studied (see section 4.2).</p><p><strong>&nbsp;</strong></p><p><strong>Pediatric population:</strong></p><p>Since safety and efficacy have not been investigated in this patient group, use of PREXET in patients less than 18 years of age is not recommended (see section 4.2).</p><p><strong>&nbsp;</strong></p><p><strong>Geriatric population:</strong></p><p>In clinical studies, there has been no indication that patients 65 years of age or older are at increased risk of adverse events compared to patients younger than 65 years old. No dose reductions other than those recommended for all patients are necessary (see section 4.2).</p><p>&nbsp;</p><p><strong>Reporting of suspected adverse reactions</strong></p><p>The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>&bull; Fax: +966-11-205-7662</p><p>&bull; Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>&bull; Toll free phone: 8002490000</p><p>&bull; E-mail: npc.drug@sfda.gov.sa</p><p>&bull; Website: www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>Reported symptoms of overdose include neutropenia, anemia, thrombocytopenia, mucositis, sensory polyneuropathy and rash. Anticipated complications of overdose include bone marrow suppression as manifested by neutropenia, thrombocytopenia and anemia. In addition, infection with or without fever, diarrhea, and/or mucositis may be seen. In the event of suspected overdose, patients should be monitored with blood counts and should receive supportive therapy as necessary.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group&nbsp;&nbsp;&nbsp;&nbsp; : Folic acid analogues</p><p>ATC code&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; : L01BA04</p><p>&nbsp;</p><p>PREXET (pemetrexed) is a multi-targeted anti-cancer antifolate agent that exerts its action by disrupting crucial folate-dependent metabolic processes essential for cell replication.</p><p>&nbsp;</p><p><em>In vitro</em> studies have shown that pemetrexed behaves as a multi-targeted antifolate by inhibiting thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), which are key folate-dependent enzymes for the <em>de novo</em> biosynthesis of thymidine and purine nucleotides. Pemetrexed is transported into cells by both the reduced folate carrier and membrane folate binding protein transport systems. Once in the cell, pemetrexed is rapidly and efficiently converted to polyglutamate forms by the enzyme folylpolyglutamate synthetase. The polyglutamate forms are retained in cells and are even more potent inhibitors of TS and GARFT. Polyglutamation is a time- and concentration-dependent process that occurs in tumor cells and, to a lesser extent, in normal tissues. Polyglutamated metabolites have an increased intracellular half-life resulting in prolonged drug action in malignant cells.</p><p>&nbsp;</p><p>Clinical efficacy:</p><p>Mesothelioma:</p><p>EMPHACIS, a multi-centre, randomized, single-blind Phase 3 study of pemetrexed plus cisplatin versus cisplatin in chemonaive patients with malignant pleural mesothelioma, has shown that patients treated with pemetrexed and cisplatin had a clinically meaningful 2.8-month median survival advantage over patients receiving cisplatin alone.</p><p>&nbsp;</p><p>The primary analysis of this study was performed on the population of all patients randomly assigned to a treatment arm who received study drug (randomized and treated). The results of these analyses of efficacy are summarized in the table below:</p><p>&nbsp;</p><p><strong>Efficacy of pemetrexed plus cisplatin combination vs. cisplatin in malignant pleural mesothelioma</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:652px"><tbody><tr><td><p>&nbsp;</p></td><td colspan="2"><p><strong>Randomized and treated patients</strong></p></td><td colspan="2"><p><strong>Fully supplemented patients</strong></p></td></tr><tr><td><p>Efficacy parameter</p></td><td><p>Pemetrexed</p><p>/Cisplatin</p><p>(N=226)</p></td><td><p>Cisplatin</p><p>(N=222)</p></td><td><p>Pemetrexed</p><p>/Cisplatin</p><p>(N=168)</p></td><td><p>Cisplatin</p><p>(N=163)</p></td></tr><tr><td><p>Median overall survival (months)</p><p>(% 95 CI)</p></td><td><p>12.1</p><p>(10.0-14.4)</p></td><td><p>9.3</p><p>(7.8-10.7)</p></td><td><p>13.3</p><p>(11.4-14.9)</p></td><td><p>10.0</p><p>(8.4-11.9)</p></td></tr><tr><td><p>Log Rank p-value*</p></td><td colspan="2"><p>0.020</p></td><td colspan="2"><p>0.051</p></td></tr><tr><td><p>Median time to tumor progression (months) (% 95 CI)</p></td><td><p>5.7</p><p>(4.9-6.5)</p></td><td><p>3.9</p><p>(2.8-4.4)</p></td><td><p>6.1</p><p>(5.3-7.0)</p></td><td><p>3.9</p><p>(2.8-4.5)</p></td></tr><tr><td><p>Log Rank p-value*</p></td><td colspan="2"><p>0.001</p></td><td colspan="2"><p>0.008</p></td></tr><tr><td><p>Time to treatment failure (months)</p><p>(% 95 CI)</p></td><td><p>4.5</p><p>(3.9-4.9)</p></td><td><p>2.7</p><p>(2.1-2.9)</p></td><td><p>4.7</p><p>(4.3-5.6)</p></td><td><p>2.7</p><p>(2.2-3.1)</p></td></tr><tr><td><p>Log Rank p-value*</p></td><td colspan="2"><p>0.001</p></td><td colspan="2"><p>0.001</p></td></tr><tr><td><p>Overall response rate** (% 95 CI)</p></td><td><p>% 41.3</p><p>(34.8-48.1)</p></td><td><p>%16.7</p><p>(12.0-22.2)</p></td><td><p>%45.5</p><p>(37.8-53.4)</p></td><td><p>%19.6</p><p>(13.8-26.6)</p></td></tr><tr><td><p>Fisher&rsquo;s exact p-value*</p></td><td colspan="2"><p>&lt; 0.001</p></td><td colspan="2"><p>&lt; 0.001</p></td></tr></tbody></table><p>Abbreviations: CI=confidence interval</p><p>&nbsp;*p-value refers to comparison between arms</p><p>** In the pemetrexed/cisplatin arm, randomized and treated (N=225) and fully supplemented (N=167)</p><p>&nbsp;</p><p>A statistically significant improvement of the clinically relevant symptoms (pain and dyspnea) associated with malignant pleural mesothelioma in the pemetrexed/cisplatin arm (212 patients) versus the cisplatin arm alone (218 patients) was demonstrated using the Lung Cancer Symptom Scale. Statistically significant improvements in pulmonary function tests were also observed.</p><p>&nbsp;</p><p>Second-line non-small cell lung cancer:</p><p>A multi-centre, randomized, open label phase 3 study of pemetrexed versus docetaxel in patients with locally advanced or metastatic non-small cell lung cancer after prior chemotherapy has shown median survival times of 8.3 months for patients treated with pemetrexed (Intent To Treat population (ITT); n=283) and 7.9 months for patients treated with docetaxel (ITT n=288). Prior chemotherapy did not include pemetrexed. An analysis of the impact of non-small cell lung cancer histology on the treatment effect on overall survival was in favor of pemetrexed versus docetaxel for other than predominantly squamous histologies (n=399, 9.3 versus 8.0 months, adjusted HR=0.78; 95% CI=0 .61-1.00, p=0.047) and was in favor of docetaxel for squamous cell carcinoma histology (n=172, 6.2 versus 7.4 months, adjusted HR=1.56; 95% CI=1.08-2.26, p=0.018). There were no clinically relevant differences observed for the safety profile of pemetrexed within the histology subgroups.</p><p><strong>&nbsp;</strong></p><p><strong>Efficacy of pemetrexed vs. docetaxel in non-small cell lung cancer - ITT population</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:652px"><tbody><tr><td><p><strong>&nbsp;</strong></p></td><td><p><strong>Pemetrexed</strong></p></td><td><p><strong>Docetaxel</strong></p></td></tr><tr><td><p><strong>Survival time (months)</strong></p></td><td><p>(n=283)</p></td><td><p>(n=288)</p></td></tr><tr><td><p>Median (m)</p></td><td><p>8.3</p></td><td><p>7.9</p></td></tr><tr><td><p>95% CI for median</p></td><td><p>(7.0-9.4)</p></td><td><p>(6.3-9.2)</p></td></tr><tr><td><p>HR</p></td><td colspan="2"><p>0.99</p></td></tr><tr><td><p>95% CI for HR</p></td><td colspan="2"><p>(.82-1.20)</p></td></tr><tr><td><p>Non-inferiority p-value (TO)</p></td><td colspan="2"><p>.226</p></td></tr><tr><td><p><strong>Progression free survival (months)</strong></p></td><td><p>(n=283)</p></td><td><p>(n=288)</p></td></tr><tr><td><p>Median</p></td><td><p>2.9</p></td><td><p>2.9</p></td></tr><tr><td><p>HR (95% CI)</p></td><td colspan="2"><p>0.97 (.82-1.16)</p></td></tr><tr><td><p><strong>Time to treatment failure (TTTF-months)</strong></p></td><td><p>(n=283)</p></td><td><p>(n=288)</p></td></tr><tr><td><p>Median</p></td><td><p>2.3</p></td><td><p>2.1</p></td></tr><tr><td><p>HR (95% CI)</p></td><td colspan="2"><p>0.84 (.71-.997)</p></td></tr><tr><td><p><strong>Response </strong>(n: qualified for response)</p></td><td><p>(n=264)</p></td><td><p>(n=274)</p></td></tr><tr><td><p>Response rate (%) ( 95% CI)</p></td><td><p>9.1 (5.9-13.2)</p></td><td><p>8.8 (5.7-12.8)</p></td></tr><tr><td><p>Stable disease (%)</p></td><td><p>45.8</p></td><td><p>46.4</p></td></tr></tbody></table><p>Abbreviations: CI=confidence interval; HR=hazard ratio; ITT=intent to treat; n=total population size</p><p>&nbsp;</p><p>First-line non-small cell lung cancer:</p><p>A multi-centre, randomized, open-label, Phase 3 study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemonaive patients with locally advanced or metastatic (Stage IIIb or IV) non-small cell lung cancer showed that pemetrexed plus cisplatin (Intent-To-Treat [ITT] population n=862) met its primary endpoint and showed similar clinical efficacy as gemcitabine plus cisplatin (ITT n=863) in overall survival (adjusted hazard ratio 0.94; 95% CI=0.84-1.05). All patients included in this study had an ECOG performance status 0 or 1.</p><p>&nbsp;</p><p>Progression free survival and overall response rate were similar between treatment arms: Median PFS was 4.8 months for pemetrexed plus cisplatin versus 5.1 months for gemcitabine plus cisplatin (adjusted hazard ratio 1.04; 95% CI=0.94-1.15), and overall response rate was 30.6% (95% CI=27.3-33.9) for pemetrexed plus cisplatin versus 28.2% (95% CI=25.0-31.4) for gemcitabine plus cisplatin. PFS data were partially confirmed by an independent review (400/1725 patients were randomly selected for review).</p><p>&nbsp;</p><p>The analysis of the impact of non-small cell lung cancer histology on overall survival demonstrated clinically relevant differences in survival according to histology, see table below.</p><p><strong>&nbsp;</strong></p><p><strong>Efficacy of Pemetrexed + Cisplatin vs. Gemcitabine + Cisplatin In First-Line Non-small Cell Lung Cancer &ndash; ITT Population and Histology Subgroups</strong></p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:662px"><tbody><tr><td rowspan="2"><p><strong>ITT Population</strong></p><p><strong>and Histology</strong></p><p><strong>Subgroups</strong></p></td><td colspan="4"><p><strong>Median Overall Survival in Months</strong></p><p><strong>(95% CI)</strong></p></td><td rowspan="2"><p><strong>Adjusted Hazard Ratio </strong></p><p><strong>(HR)</strong></p><p><strong>(95% CI)</strong></p></td><td rowspan="2"><p><strong>Superiority</strong></p><p><strong>p-value</strong></p></td></tr><tr><td colspan="2"><p><strong>Pemetrexed + Cisplatin</strong></p></td><td colspan="2"><p><strong>Gemcitabine + Cisplatin</strong></p></td></tr><tr><td><p>ITT Population</p><p>(N=1725)</p></td><td><p>10.3</p><p>(9.8-11.2)</p></td><td><p>N=862</p></td><td><p>10.3</p><p>(9.6-10.9)</p></td><td><p>N=863</p></td><td><p>0.94<sup>a</sup></p><p>(0.84-1.05)</p></td><td><p>0.259</p></td></tr><tr><td><p>Adenocarcinoma</p><p>(N=847)</p></td><td><p>12.6</p><p>(10.7-13.6)</p></td><td><p>N=436</p></td><td><p>10.9</p><p>(10.2-11.9)</p></td><td><p>N=411</p></td><td><p>0.84</p><p>(0.71-0.99)</p></td><td><p>0.033</p></td></tr><tr><td><p>Large Cell</p><p>(N=153)</p></td><td><p>10.4</p><p>(8.6- 14.1)</p></td><td><p>N=76</p></td><td><p>6.7</p><p>(5.5- 9.0)</p></td><td><p>N=77</p></td><td><p>0.67</p><p>(0.48-0.96)</p></td><td><p>0.027</p></td></tr><tr><td><p>Other</p><p>(N=252)</p></td><td><p>8.6</p><p>(6.8- 10.2)</p></td><td><p>N=106</p></td><td><p>9.2</p><p>(8.1- 10.6)</p></td><td><p>N=146</p></td><td><p>1.08</p><p>(0.81-1.45)</p></td><td><p>0.586</p></td></tr><tr><td><p>Squamous Cell</p><p>(N=473)</p></td><td><p>9.4</p><p>(8.4- 10.2)</p></td><td><p>N=244</p></td><td><p>10.8</p><p>(9.5- 12.1)</p></td><td><p>N=229</p></td><td><p>1.23</p><p>(1.00-1.51)</p></td><td><p>0.050</p></td></tr></tbody></table><p>Abbreviations: CI=confidence interval; HR=hazard ratio; ITT=intent to treat; N=total population size</p><p><sup>a</sup> Statistically significant for non-inferiority, with the entire confidence interval for HR well below the 1.17645 non-inferiority margin (p&lt;0.001).</p><p>&nbsp;</p><p>Kaplan Meier Plots of Overall Survival by Histology</p><p>&nbsp;</p><p><img alt="" width="609" height="802" src="data:image/png;base64,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" /></p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_2" o:spid="_x0000_i1025" type="#_x0000_t75"
 style='width:375.6pt;height:150.6pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/ph-a-/AppData/Local/Packages/oice_16_974fa576_32c1d314_294c/AC/Temp/msohtmlclip1/01/clip_image001.jpg"
  o:title="1"/>
</v:shape><![endif]--></p><p>There were no clinically relevant differences observed for the safety profile of pemetrexed plus cisplatin within the histology subgroups.</p><p>&nbsp;</p><p>Patients treated with pemetrexed and cisplatin required fewer transfusions (16.4% versus 28.9%, p&lt;0.001), red blood cell transfusions (16.1% versus 27.3%, p&lt;0.001) and platelet transfusions (1.8% versus 4.5%, p=0.002). Patients also required lower administration of erythropoietin/darbopoietin (10.4% versus 18.1%, p&lt;0.001), G-CSF/GM-CSF (3.1% versus 6.1%, p=0.004), and iron preparations (4.3% versus 7.0%, p=0.021).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption:</u></p><p>The pharmacokinetic properties of pemetrexed following single-agent administration have been evaluated in 426 cancer patients with a variety of solid tumors at doses ranging from 0.2 to 838 mg/m<sup>2 </sup>infused over a 10-minute period. Pemetrexed total systemic exposure (AUC) and maximum plasma concentration increase proportionally with dose. The pharmacokinetics of pemetrexed are consistent over multiple treatment cycles.</p><p>&nbsp;</p><p><u>Distribution:</u></p><p>Pemetrexed has a steady-state volume of distribution of 9 L/m<sup>2</sup>. <em>In vitro</em> studies indicate that pemetrexed is approximately 81% bound to plasma proteins. Binding was not notably affected by varying degrees of renal impairment.</p><p>&nbsp;</p><p><u>Biotransformation:</u></p><p>Pemetrexed undergoes limited hepatic metabolism.</p><p><u>&nbsp;</u></p><p><u>Elimination:</u></p><p>Pemetrexed is primarily eliminated in the urine, with 70% to 90% of the administered dose being recovered unchanged in urine within the first 24 hours following administration. Pemetrexed total systemic clearance is 91.8 ml/min and the elimination half-life from plasma is 3.5 hours in patients with normal renal function (creatinine clearance of 90 ml/min). Between patient variability in clearance is moderate at 19.3%.</p><p>&nbsp;</p><p><u>Linearity/non-linearity:</u></p><p>Pemetrexed total area under curve (AUC) and maximum plasma concentration increase proportionally with dose. The pharmacokinetics of pemetrexed are consistent over multiple treatment cycles.</p><p><em>&nbsp;</em></p><p><strong>Pharmacokinetic/pharmacodynamic relationship(s)</strong></p><p>The pharmacokinetic properties of pemetrexed are not influenced by concurrently administered cisplatin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Administration of pemetrexed to pregnant mice resulted in decreased fetal viability, decreased fetal weight, incomplete ossification of some skeletal structures and cleft palate.</p><p>&nbsp;</p><p>Administration of pemetrexed to male mice resulted in reproductive toxicity characterized by reduced fertility rates and testicular atrophy. In a study conducted in beagle dog by intravenous bolus injection for 9 months, testicular findings (degeneration/necrosis of the seminiferous epithelium) have been observed. This suggests that pemetrexed may impair male fertility. Female fertility was not investigated.</p><p>&nbsp;</p><p>Pemetrexed was not mutagenic in either the <em>in vitro</em> chromosome aberration test in Chinese hamster ovary cells, or the Ames test. Pemetrexed has been shown to be clastogenic in the <em>in vivo</em> micronucleus test in the mouse.</p><p>&nbsp;</p><p>Studies to assess the carcinogenic potential of pemetrexed have not been conducted.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mannitol</p><p>Hydrochloric acid</p><p>Sodium hydroxide</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pemetrexed is physically incompatible with diluents containing calcium, including lactated Ringer&rsquo;s injection and Ringer&rsquo;s injection. In the absence of compatibility studies with other medicines and diluents, this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Unopened vial:
36 months

Reconstituted and diluted medicinal product: 
When prepared as directed, reconstituted infusion solutions of PREXET contain no antimicrobial preservatives. Chemical and physical in-use stability of infusion solutions of pemetrexed is 24 hours at 2°C to 8°C. From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not more than 24 hours at 2–8 °C unless reconstitution/dilution has taken place under controlled and validated aseptic conditions.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Chemical and physical in-use stability of infusion solutions of pemetrexed is 24 hours at 2&ndash;8 &deg;C. Solution for infusion is stable up to 24 hours at 2&ndash;8 &deg;C after reconstitution.</p><p><u>&nbsp;</u></p><p>Unopened vial:</p><p>Store at room temperature below 30&deg;C and in its package.</p><p>&nbsp;</p><p>Reconstituted infusion solutions:</p><p>For storage conditions after reconstitution of the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lyophilized powder in colorless 50 ml Type I glass vial with rubber stopper and flip-off aluminum cap, in protective blister separator, containing 500 mg pemetrexed. Available in packs of 1 vial accompanied by patient information leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>1.&nbsp;&nbsp; </strong>Use aseptic technique during the reconstitution and further dilution of pemetrexed for intravenous infusion administration.</p><p><strong>2.&nbsp;&nbsp; </strong>Calculate the dose and the number of PREXET vials needed. Each vial contains an excess of pemetrexed to facilitate delivery of label amount.</p><p><strong>3.&nbsp;&nbsp; </strong>Reconstitute 50 ml vials with 20 ml of sodium chloride 9 mg/ml (0.9%) solution for injection, resulting in a solution containing 25 mg/ml pemetrexed. Gently swirl each vial until the powder is completely dissolved. The resulting solution is clear and ranges in color from colorless to yellow or green-yellow without adversely affecting product quality. The pH of the reconstituted solution is between 6.6 and 7.8. <strong>Further dilution is required.</strong></p><p><strong>4.&nbsp;&nbsp; </strong>The appropriate volume of reconstituted pemetrexed solution must be further diluted to 100 ml with sodium chloride 9 mg/ml (0.9%) solution for injection, and administered as an intravenous infusion over 10 minutes.</p><p><strong>5.&nbsp;&nbsp; </strong>Pemetrexed infusion solutions prepared as directed above are compatible with glass infusion bottles, polyvinyl chloride- and polyolefin- lined administration sets and infusion bags.</p><p><strong>6.&nbsp;&nbsp; </strong>Parenteral medicinal products must be inspected visually for particulate matter and discoloration prior to administration. If particulate matter is observed, do not administer.</p><p><strong>7.&nbsp;&nbsp; </strong>Pemetrexed solutions are for single use only. Any unused medicinal product or waste material must be disposed of in accordance with local requirements.</p><p><strong>&nbsp;</strong></p><p><strong>Preparation and administration precautions:</strong> As with other potentially toxic anticancer agents, care should be exercised in the handling and preparation of pemetrexed infusion solutions. The use of gloves is recommended. If a pemetrexed solution contacts the skin, wash the skin immediately and thoroughly with soap and water. If pemetrexed solutions contact the mucous membranes, flush thoroughly with water. Pemetrexed is not a vesicant. There is not a specific antidote for extravasation of pemetrexed. There have been few reported cases of pemetrexed extravasation, which were not assessed as serious by the investigator. Extravasation should be managed by local standard practice as with other non-vesicants.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MN Pharmaceuticals
Prof. Dr. Bülent Tarcan Sok., Pak İş Merkezi No: 5/1
34349 Gayrettepe-İstanbul/TURKEY

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                12/2018
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>